Today: 18 June 2026
Browse Category

NASDAQ:ARWR 25 November 2025 - 9 February 2026

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals shares fell about 9% Tuesday, trading near $62 after touching an intraday low of $59.76. The decline follows a recent surge to a 52-week high after FDA approval of its first drug, REDEMPLO, and an FDA Breakthrough Therapy designation. No single negative catalyst was cited; analysts pointed to profit-taking and volatility after recent gains. Arrowhead also disclosed routine equity grants for new hires.
16 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals stock surged to a 52-week high of $71.5 on December 8, 2025, after securing its first FDA approval for REDEMPLO and announcing a major Novartis licensing deal. Shares traded around $69 on December 9, up over 260% year-to-date, with market value near $9.5 billion. Trading volume more than doubled typical levels. The company also began dosing in an Alzheimer’s trial.
9 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals shares jumped 14–15% intraday on 8 December 2025, reaching a 52-week high near $69 after dosing the first subjects in its Alzheimer’s trial ARO-MAPT. The stock has returned about 270% year-to-date, with a market cap around $9–9.6 billion. The Phase 1/2a trial targets tau protein using Arrowhead’s RNAi platform. Liquidity ratios stand near 4.8, with beta between 1.3 and 1.5.
8 December 2025
·
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····

Stock Market Today

  • Western Digital's 1089% Surge Driven by AI Data Storage Demand
    June 18, 2026, 10:23 AM EDT. Western Digital (WDC) soared over 1,000% in a year, vastly outperforming the S&P 500 and peers like Seagate and Micron. The company's transformation from a commodity hardware maker to a premium AI infrastructure provider is central to this jump. Its April earnings showed 45% revenue growth and a rare 50.5% adjusted gross margin, reflecting strong demand for data storage driven by AI training and inference needs. Long-term contracts extending to 2029 signal locked-in customer demand amid cloud providers securing AI capacity. Despite investor enthusiasm, analysts remain cautious about cost cuts and margin sustainability as new storage technologies roll out gradually. WDC's run highlights the growing importance of data landlords in the AI economy and poses questions about the stock's pricing ahead of a full technology transition.

Latest articles

Energy Fuels Stock Jumps as $725 Million U.S. Loan Commitment Lifts Rare Earth Plans

Energy Fuels Stock Jumps as $725 Million U.S. Loan Commitment Lifts Rare Earth Plans

18 June 2026
Energy Fuels surged 10% to $16.84 after a conditional U.S. government loan commitment of up to $725 million for White Mesa Mill expansion and a planned U.S. rare earth facility, outpacing uranium and rare earth peers; the loan remains subject to due diligence, final agreements, and approvals, with risks including commodity prices, permitting, and execution flagged by the company.
Kroger edges down after it sticks to 2026 guidance

Kroger edges down after it sticks to 2026 guidance

18 June 2026
Kroger shares fell about 3% in premarket trading after first-quarter adjusted profit missed estimates by a cent despite a sales beat, as margin pressure from price cuts and higher transport costs raised investor doubts about CEO Greg Foran’s strategy to win back shoppers from Walmart and Costco.
Go toTop